1-2 of 2
Lazaros Lekakis, MD
Close
Sort by
Journal Articles

Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1

Sattva S. Neelapu, MD, Frederick L. Locke, MD, Nancy L. Bartlett, MD, Lazaros Lekakis, MD, David Miklos, MD PhD, Caron A. Jacobson, MD, Ira Braunschweig, MD, Olalekan Oluwole, MBBS, MPH, Tanya Siddiqi, MD, Yi Lin, MD PhD, John Timmerman, MD, Patrick J. Stiff, Jonathan Friedberg, MD, Ian Flinn, Andre Goy, MD, Mitchell Smith, Abhinav Deol, MD, Umar Farooq, MD, Peter McSweeney, MD, Javier Munoz, MD, Irit Avivi, MD, Januario E. Castro, MD, Jason R. Westin, MD MS, Julio C. Chavez, MD, Armin Ghobadi, MD, Krishna V. Komanduri, MD, Ronald Levy, MD, Eric D. Jacobsen, Patrick Reagan, MD, Adrian Bot, MD PhD, John M. Rossi, MS, Lynn Navale, MS, Yizhou Jiang, PhD, Jeff S. Aycock, BA, Meg Elias, RN, BSN, Jeff Wiezorek, MD MS, William Y. Go, MD PhD
Journal: Blood
Blood (2016) 128 (22): LBA-6.
https://doi.org/10.1182/blood.V128.22.LBA-6.LBA-6
Published: 2016
Journal Articles

Phase I Study of the Novel Surivin and cdc2/CDK1 Inhibitor Terameprocol in Patients with Advanced Leukemias.

Raoul Tibes, MD, PhD, Kevin T. McDonagh, MD, Lazaros Lekakis, MD, Neal Frazer, MD, Scott Mohrland, PhD, Bassett Dawn, RN, Reynaldo Garcia, RN, OCN, Katy Schroeder, RN, Vijayalakshmi Shanmugam, John Carpten, Daniel Von Hoff, MD, FACP, Thomas C. Shea, MD
Journal: Blood
Blood (2009) 114 (22): 1039.
https://doi.org/10.1182/blood.V114.22.1039.1039
Published: 2009